A Second-Generation (44-Channel) Suprachoroidal Retinal Prosthesis: A Single-Arm Clinical Trial of Feasibility

被引:3
|
作者
Petoe, Matthew A. [1 ]
Abbott, Carla J. [2 ,3 ,4 ]
Titchener, Samuel A. [1 ]
Kolic, Maria [3 ]
Kentler, William G. [5 ]
Nayagam, David A. X. [1 ,3 ,6 ]
Baglin, Elizabeth K. [3 ]
Kvansakul, Jessica [1 ]
Barnes, Nick [7 ]
Walker, Janine G. [7 ,8 ]
Karapanos, Lewis [3 ,4 ,9 ]
McGuinness, Myra B. [3 ,4 ]
Ayton, Lauren N. [3 ,4 ]
Luu, Chi D. [3 ,4 ]
Allen, Penelope J. [3 ,4 ,10 ]
机构
[1] Bion Inst, Melbourne, Vic, Australia
[2] Univ Melbourne, Med Dept Bion, Melbourne, Vic, Australia
[3] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia
[4] Univ Melbourne, Dept Surg, Ophthalmol, Melbourne, Vic, Australia
[5] Univ Melbourne, Dept Biomed Engn, Melbourne, Vic, Australia
[6] Univ Melbourne, St Vincents Hosp, Dept Pathol, Melbourne, Vic, Australia
[7] Australian Natl Univ, Res Sch Engn, Canberra, ACT, Australia
[8] CSIRO, Hlth & Biosecur, Canberra, ACT, Australia
[9] Univ Melbourne, Dept Optometry & Vis Sci, Melbourne, Australia
[10] Royal Victorian Eye & Ear Hosp, Vitreoretinal Unit, Melbourne, Australia
来源
OPHTHALMOLOGY SCIENCE | 2025年 / 5卷 / 01期
基金
英国医学研究理事会;
关键词
Suprachoroidal retinal prosthesis; Functional vision; Bionic eye; Retinitis; pigmentosa; QUALITY-OF-LIFE; FUNCTIONAL VISION; BLIND SUBJECTS; VISUAL PERFORMANCE; SYSTEM; PART;
D O I
10.1016/j.xops.2024.100525
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To assess the feasibility of a second-generation (44-channel) suprachoroidal retinal prosthesis for provision of functional vision in recipients with end-stage retinitis pigmentosa (RP) over 2.7 years. Design: Prospective, single-arm, unmasked interventional clinical trial. Participants: Four participants, with advanced RP and bare-light perception vision. Methods: The 44-channel suprachoroidal retinal prosthesis was implanted in the worse-seeing eye. Device stability, functionality, and adverse events were investigated at approximately 12-week intervals up to 140 weeks (2.7 years) postdevice activation. Main Outcome Measures: Serious adverse event (SAE) reporting, visual response outcomes, functional vision outcomes, and quality-of-life outcomes. Results: All 4 participants (aged 39-66 years, 3 males) were successfully implanted in 2018, and there were no device-related SAEs over the duration of the study. A mild postoperative subretinal hemorrhage was detected in 2 recipients, which cleared spontaneously within 2 weeks. OCT confirmed device stability and position under the macula. Improvements in localization abilities were demonstrated for all 4 participants in screen-based, tabletop, and orientation and mobility tasks. In addition, 3 of 4 participants recorded improvements in motion discrimination and 2 of 4 participants recorded substantial improvements in spatial discrimination and identification of tabletop objects. Participants reported their unsupervised use of the device included exploring new environments, detecting people, and safely navigating around obstacles. A positive effect of the implant on participants' daily lives in their local environments was confirmed by an orientation and mobility assessor and participant self-report. Emotional well-being was not impacted by device implantation or usage. Conclusions: The completed clinical study demonstrates that the suprachoroidal prosthesis raises no safety concerns and provides improvements in functional vision, activities of daily living, and observer-rated quality of life. (c) 2024 by the American Academy of Ophthalmology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/ licenses/by-nc-nd/4.0/).
引用
收藏
页数:17
相关论文
共 49 条
  • [21] Feasibility and tolerability of sintilimab plus anlotinib as the second-line therapy for patients with advanced biliary tract cancers: An open-label, single-arm, phase II clinical trial
    Jin, Shuiling
    Zhao, Ruihua
    Zhou, Chuang
    Zhong, Qian
    Shi, Jianxiang
    Su, Chang
    Li, Qinglong
    Su, Xiaoxing
    Chi, Huabin
    Lu, Xu
    Jiang, Guozhong
    Chen, Renyin
    Han, Jinming
    Jiang, Miao
    Qiao, Shishi
    Liu, Jingjing
    Song, Min
    Song, Lijie
    Du, Yabing
    Chang, Zhiwei
    Wang, Meng
    Dong, Meilian
    Zhong, Yali
    Yu, Pu
    Zhang, Xiaojian
    Zong, Hong
    INTERNATIONAL JOURNAL OF CANCER, 2023, 152 (08) : 1648 - 1658
  • [22] Feasibility, clinical efficacy, and well-being outcomes of an online singing intervention for postnatal depression in the UK: SHAPER-PNDO, a single-arm clinical trial
    Rebecca H. Bind
    Kristi Sawyer
    Katie Hazelgrove
    Lavinia Rebecchini
    Celeste Miller
    Subeyda Ahmed
    Paola Dazzan
    Nick Sevdalis
    Ioannis Bakolis
    Rachel Davis
    Maria Baldellou Lopez
    Anthony Woods
    Nikki Crane
    Manonmani Manoharan
    Alexandra Burton
    Hannah Dye
    Tim Osborn
    Lorna Greenwood
    Rosie Perkins
    Daisy Fancourt
    Carmine M. Pariante
    Carolina Estevao
    Pilot and Feasibility Studies, 9
  • [23] Feasibility, clinical efficacy, and well-being outcomes of an online singing intervention for postnatal depression in the UK: SHAPER-PNDO, a single-arm clinical trial
    Bind, Rebecca H.
    Sawyer, Kristi
    Hazelgrove, Katie
    Rebecchini, Lavinia
    Miller, Celeste
    Ahmed, Subeyda
    Dazzan, Paola
    Sevdalis, Nick
    Bakolis, Ioannis
    Davis, Rachel
    Lopez, Maria Baldellou
    Woods, Anthony
    Crane, Nikki
    Manoharan, Manonmani
    Burton, Alexandra
    Dye, Hannah
    Osborn, Tim
    Greenwood, Lorna
    Perkins, Rosie
    Fancourt, Daisy
    Pariante, Carmine M.
    Estevao, Carolina
    PILOT AND FEASIBILITY STUDIES, 2023, 9 (01)
  • [24] Emotional awareness and expression therapy (EAET) for chronic pain following traumatic orthopaedic injury and surgery: study protocol for a single-arm feasibility clinical trial
    Ravyts, Scott G.
    Carnahan, Nicolette
    Campbell, Claudia
    Castillo, Renan
    Wegener, Stephen
    Rassu, Fenan S.
    Lumley, Mark A.
    Aaron, Rachel
    BMJ OPEN, 2025, 15 (03):
  • [25] A single-arm clinical trial investigating the feasibility of the zygomatic implant quad approach for Cawood and Howell Class 4 edentulous maxilla: An option for immediate loading
    Wang, Feng
    Tao, Baoxin
    Shen, Yihan
    Li, Chaolun
    Huang, Wei
    Sun, Yuanyuan
    Wu, Yiqun
    CLINICAL IMPLANT DENTISTRY AND RELATED RESEARCH, 2021, 23 (05) : 800 - 808
  • [26] A Research Protocol for a Phase II Single-Arm Clinical Trial Assessing the Feasibility and Efficacy of Neoadjuvant Anastrozole in Patients With Luminal Breast Cancer and Low Proliferative Index: The ANNE Trial
    Paiva, Carlos Eduardo
    Silva, Alinne Tatiane Faria
    Oliveira, Izabella da Silva
    Guimaraes, Vitor Souza
    Lacerda, Domicio Carvalho
    Teixeira, Gustavo Ramos
    Watanabe, Anapaula Hidemi Uema
    Onari, Nilton
    Paiva, Bianca Sakamoto Ribeiro
    Oliveira-Junior, Idam de
    Marques, Marcia Maria Chiquitelli
    Maia, Yara Cristina de Paiva
    CANCER CONTROL, 2024, 31
  • [27] A second-generation artificial intelligence-based therapeutic regimen improves diuretic resistance in heart failure: Results of a feasibility open-labeled clinical trial
    Gelman, Ram
    Hurvitz, Noa
    Nesserat, Rima
    Kolben, Yotam
    Nachman, Dean
    Jamil, Khurram
    Agus, Samuel
    Asleh, Rabea
    Amir, Offer
    Berg, Marc
    Ilan, Yaron
    BIOMEDICINE & PHARMACOTHERAPY, 2023, 161
  • [28] Health resource utilization and cost before versus after initiation of second-generation long-acting injectable antipsychotics among adults with schizophrenia in Alberta, Canada: a retrospective, observational single-arm study
    Kai On Wong
    Scott W. Klarenbach
    Karen J. B. Martins
    Pierre Chue
    Serdar M. Dursun
    Mark Snaterse
    Alexis Guigue
    Helen So
    Huong Luu
    Khanh Vu
    Lawrence Richer
    BMC Psychiatry, 22
  • [29] Health resource utilization and cost before versus after initiation of second-generation long-acting injectable antipsychotics among adults with schizophrenia in Alberta, Canada: a retrospective, observational single-arm study
    Wong, Kai On
    Klarenbach, Scott W.
    Martins, Karen J. B.
    Chue, Pierre
    Dursun, Serdar M.
    Snaterse, Mark
    Guigue, Alexis
    So, Helen
    Luu, Huong
    Khanh Vu
    Richer, Lawrence
    BMC PSYCHIATRY, 2022, 22 (01)
  • [30] Hypofractionated radiotherapy plus PD-1 antibody and SOX chemotherapy as second-line therapy in metastatic pancreatic cancer: a single-arm, phase II clinical trial
    Wang, Qin
    Tong, Fan
    Qiao, Li
    Qi, Liang
    Sun, Yi
    Zhu, Yahui
    Ni, Jiayao
    Liu, Juan
    Kong, Weiwei
    Liu, Baorui
    Du, Juan
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (10)